Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Switzerland-based chemicals and biotechnology company Lonza has introduced a new Developability Assessment Platform, to help in early risk assessment in biopharmaceutical drug development programs.
Subscribe to our email newsletter
Designed to lessen attrition rates and improve the ranking of early drug candidates, the new system comprises both manufacturability and safety assessments for early detection of possible chemical/physical stability and immunogenicity issues.
Lonza custom development services organization head Janet White said, "This combination of manufacturability and safety assessment allows our customers to de-risk their candidates, supporting the "fail fast, fail early" mantra."
The company said that the prediction system includes an assortment of in silico based services which assess candidates for fitness for manufacturability and immunogenicity profiles in humans.
The new tool scrutinizes chemical degradation pathways and post translational modifications, including deamidation, oxidation and glycosylation, as well as potential physical stability issues, and protein aggregation.
Further, Epibase in silico screening tool recognizes possible T-cell epitopes in target proteins that may trigger potential immune reactions in human studies.